Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadInsufficient Data
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Senores Pharmaceuticals Ltd manufactures a range of pharmaceutical products, including tablets and APIs, focusing on international quality to meet global healthcare demands.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
SENORES PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Jan-2025 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2024 and Other business. | Download
SENORES PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Jan-2025 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2024 and Other business. | Download
Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 09, 2025, titled "Senores Pharmaceuticals receives ANDA approval for marketing MetoprololTartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg". | Download
Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 09, 2025, titled "Senores Pharmaceuticals receives ANDA approval for marketing MetoprololTartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg". | Download
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 20.90%